Pre-Clinical In Vitro and In Vivo Evidence to Support Personalized Biologic Treatment of Endometrial Cancer with Metformin and PI3K Pathway Inhibitors

作者：D. Iglesias, J. Burzawa, Q. Zhang, N. Co, J. Celestino, M. Yates, R. Schmandt, D. Gershenson, Kangning Lu · 发表于：Gynecologic Oncology · 年份：2012 · DOI：10.1016/j.ygyno.2012.01.023 · 研究领域：PI3K/AKT/mTOR signaling in cancer、Metabolism, Diabetes, and Cancer